Cannabinoids Treatment for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis With Bayesian and Sequential Trial Analyses. | ClinicLen
Agitation and related neuropsychiatric symptoms are common in Alzheimer's disease (AD) and contribute to caregiver burden, functional decline, and institutionalization. Cannabinoid-based therapies have been investigated as potential symptomatic interventions, but evidence re
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.